Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be ...

Pfizer's earlier buy-in only gave it ex-US rights to rimegepant, already approved and on sale in the US as Nurtec ODT, so taking control of the entire company will give it full ownership of the ...

Pfizer's Q4 adjusted EPS was $0.63 ... This was primarily driven by legacy Seagen, Vyndaqel family, Eliquis, Nurtec ODT/Vydura, and Xtandi, partially offset by lower revenues for Abrysvo, Xeljanz ...

Pfizer has agreed to pay $59,746,277.54 ... and honoraria payments to health care providers to encourage them to prescribe Nurtec ODT (Nurtec), a prescription medication for migraine treatment.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Nurtec ODT/Vydura sales jumped 39% to $392 million ... and Abrysvo RSV vaccine sales slumped 62% to $198 million. Guidance: Pfizer reaffirms 2025 revenues of $61 billion-$64 billion compared ...

Pfizer Inc. (NYSE:PFE – Get Free Report ... and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs ...

Pfizer expects to sufficiently de-lever its ... and generic competition in certain international markets; Nurtec ODT/Vydura globally, up 39% operationally, driven primarily by strong demand ...